MyMedipro Unveils Three Revolutionary DX Solutions for Healthcare Transformation

In a groundbreaking announcement, MyMedipro Co., Ltd. has unveiled three innovative digital transformation (DX) solutions poised to revolutionize the Japanese healthcare industry. The company invites influential media, YouTubers, and pharmaceutical professionals to a special presentation scheduled for Friday, April 18, 2025, where these solutions will make their debut.

Employing cutting-edge AI technology, MyMedipro has successfully developed a new system aimed at transforming online consultations and the sales activities of pharmaceutical companies. The introduction of these innovative technologies is expected to pave the way for a brighter future in the pharmaceutical sector.

Overview of the Three Innovative Solutions

1. Membership-Based Online Consultation System

The spotlight is on the newly developed membership-based online consultation system, which is generating significant attention within the Japanese healthcare landscape. Particularly effective in managing chronic diseases such as obesity and depression, this system offers two major benefits: streamlining chronic disease management and providing specialized medical services.

Breakthrough in Chronic Disease Management

The membership-based online consultation system demonstrates remarkable effectiveness in managing chronic conditions like obesity. These ailments require continuous monitoring and care, but frequent doctor visits can be burdensome for patients. "In obesity treatment, regular exchanges of information regarding dietary habits, exercise, and weight fluctuations are crucial for treatment success," healthcare professionals have noted. Through the online system, patients can now share their health data with doctors in real-time and receive timely advice.

Launch of 'ZepBound' for Obesity Treatment

A highlight of this innovation is the launch of the new obesity treatment drug 'ZepBound' on April 11, 2025. This drug is a next-generation dual incretin receptor agonist, effective in managing weight with a once-a-week dosage. With its introduction, the treatment of obesity in Japan enters a new era, supported by MyMedipro's online consultation system designed to efficiently integrate this treatment into patients' lives.

For more details about ZepBound, please visit this URL.

This marks a significant advancement in obesity treatment as Japan looks forward to comprehensive approaches being widely implemented. Appointments can be scheduled through the dedicated site here.

2. Unique Single Sign-On (SSO) System

Developed in collaboration with major IT companies, MyMedipro's SSO system for healthcare professionals is embedded within a smartphone app, allowing for centralized access to various pharmaceutical companies' member sites. This innovation alleviates the need for individual ID and password management, enabling healthcare providers to access drug information more efficiently.

MyMedipro has already applied for a patent on the Open ID system, enhancing accessibility to pharmaceutical data significantly and aiming to relieve login-related stress for many healthcare professionals—a true game-changer.

3. Innovative Games Utilized During Consultation Wait Times

MyMedipro has also developed two engaging table games to be enjoyed during waiting times for online consultations. These games are designed to provide an experience that rivals traditional ones like Othello and Shogi, aiming to increase the time physicians spend on the platform and enhance overall user experience.

According to the company’s research, incorporating games into online consultations is a world-first concept, and a patent has been applied for this innovation.

Special Presentation Details for Media and Industry Professionals

Aiming to provide in-depth insights into these revolutionary technologies, MyMedipro will host a special presentation on April 18, 2025, at the Grand Arc Hanzomon venue. This event targets influential media personnel and key executives from Japan's pharmaceutical companies, structured in three sessions: 11 AM, 1 PM, and 3 PM, with limited invitations. Influencers with over 200,000 followers who are interested in dieting are particularly encouraged to apply; the deadline for participation is April 15, 2025.

For those unable to attend, individual presentations will be arranged for pharmaceutical companies to discuss potential new promotions and detailing opportunities directly.

MyMedipro has previously worked on developing platforms for both 'online consultations' and 'online pharmacies', and has recently focused on creating unique features for B2B ‘online healthcare’ solutions, steering clear of the highly competitive B2C market. To differentiate from competitors, they are implementing a membership-based system for B2C and are emphasizing the development of SSO systems linked with smartphone apps for B2B.

By leveraging AI technology, MyMedipro aims to accelerate its development pace, culminating in an early product reveal in 2025.

Special Presentation Event Details (Organized by MyMedipro Co., Ltd.)

- Date: April 18, 2025

Session 1: 11 AM - 12 PM
Session 2: 1 PM - 2 PM
Session 3: 3 PM - 4 PM

- Location: Grand Arc Hanzomon "Hibiki"
- Target: Media representatives and pharmaceutical companies (free admission)
- Contact: [email protected] (Contact on Day: 080-3913-0826)
- Registration Deadline: April 15, 2025

We truly appreciate your time and hope you join us in experiencing the forefront of healthcare DX technology.